SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is trending as investors digest news of significant debt-to-equity conversions by leadership and board members, signaling strong insider conviction ahead of upcoming quarterly results. The community is actively debating the impact of these financial maneuvers on the balance sheet alongside the stock's potential as a key supplier for high-profile defense programs and anticipated aerospace partnerships.

Maul Coin

Maul Coin is trending as the community actively builds momentum and promotes the project across platforms in anticipation of gaining official charting support. Investors are focused on grassroots growth, burning supply, and maintaining community-driven support levels to establish the coin as a long-term meme project.

"What's Updog?" is a Community Led token.

UpDog

The UpDog community is rallying around the project's long-standing presence in the market, frequently engaging in lighthearted wordplay and community-driven social activity. Investors are actively sharing instructions for token swaps and highlighting the ticker's persistence as a key talking point in discussions across social platforms.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as investors bet on potential utility-driven growth, fueled by anticipation surrounding an upcoming industry conference and speculation about a future collaboration with Ripple. The community remains divided, with long-term holders highlighting recent ecosystem scaling and burn mechanics while skeptics dismiss the price action as a recurring pattern of volatility and speculative pumping.

NKN is building the largest blockchain for network sharing.

New Kind of Network

NKN is capturing market attention as traders speculate on potential partnership rumors and a recently announced token buyback program. While some members of the community express frustration over past price action and delisting concerns, others are actively accumulating the asset, viewing it as a low-cap opportunity with potential for a short-squeeze recovery.

Agnico Eagle Mines Ltd. engages in the exploration and production of gold. It operates through the following segments: Northern Business, Southern Business, and Exploration. The Northern Business segment comprises of LaRonde mine, LaRonde Zone 5 mine, Lapa mine, Goldex mine, Meadowbank mine including the Amaruq deposit, Canadian Malartic joint operation, Meliadine project and Kittila mine. The Southern Business segment consists of Pinos Altos mine, Creston Mascota mine, and La India mine. The Exploration segment represents the exploration offices in the United States, Europe, Canada, and Latin America. The company was founded by Paul Penna in 1957 and is headquartered in Toronto, Canada.

Agnico Eagle Mines Ltd

Agnico Eagle Mines is currently trending as a leading gold producer, buoyed by the stock's strong momentum, record cash flows, and its status as a top-ranked pick among investors seeking quality exposure to rising gold prices. Market participants are actively discussing the company's robust balance sheet and strategic growth projects, which many view as a hedge against global fiscal uncertainty and fiat currency devaluation.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is currently a focal point for investors due to persistent speculation regarding a potential buyout by major shareholders and intense activity from short sellers. The community remains deeply divided, with some betting on a long-term turnaround fueled by international expansion and an attractive dividend yield, while others are frustrated by the lack of permanent CEO leadership and ongoing operational struggles.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin ($BNKR) is attracting significant investor attention as a key infrastructure play for autonomous onchain AI agents within the Base ecosystem. Community sentiment remains bullish, with many users focusing on the project's growing utility, recurring revenue from transaction fees, and the strategic expansion of its agent-based trading capabilities.

United States Brent Oil Fund LP - Units

United States Commodity Funds LLC - United States Brent Crude Oil Fund

The United States Brent Oil Fund (BNO) is experiencing heightened volatility and significant trading volume as market participants grapple with ongoing geopolitical instability in the Middle East and concerns over oil supply chokepoints. Community discussions are heavily focused on the impact of conflict in the Strait of Hormuz, with many debating the sustainability of current oil prices and the likelihood of further supply shocks.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending following its Q4 2025 earnings report, which highlighted strong IBSRELA revenue growth and increased 2026 operating expenses, dividing community opinion while insider buying and a new LPGA partnership add to the conversation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Q1 EPS Estimate for Enliven Therapeutics Reduced by Analyst

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) - HC Wainwright dropped their Q1 2026 earnings per share (EPS) estimates for Enliven Therapeutics in a note issued to investors on Thursday...

Enliven Therapeutics (NASDAQ:ELVN) Given New $56.00 Price Target at HC Wainwright

HC Wainwright upped their price target on Enliven Therapeutics from $48.00 to $56.00 and gave the stock a "buy" rating in a research report on Thursday...

Enliven Therapeutics (NASDAQ:ELVN) Hits New 12-Month High on Analyst Upgrade

Enliven Therapeutics (NASDAQ:ELVN) Sets New 12-Month High Following Analyst Upgrade...

<ul class="summary-bullets"><li>Enliven's ELVN-001 is a high-potential investigational therapy with a best-in-class profile, offering a complementary mechanism to the approaches of Novartis’s Asciminib and TERN-701, the analyst said.&nbsp;</li><li>Clear sees ELVN-001 as a lower-risk, high-upside asset.</li><li>The late-stage ENABLE-2 trial of ELVN-001 in second line and beyond CML remains on track for the second half of 2026 initiation.</li></ul>Shares of Enliven Therapeutics Inc (ELVN) rallied 15% on Wednesday after Wall Street highlighted that Merck's (MRK) $6.7 billion acquisition of Terns Pharmaceuticals' (TERN) TERN-701 underscores the unmet need and opportunity for safer, more effective chronic myeloid leukemia (CML) therapies, similar to the kind Enliven is developing.Clear Street noted the opportunity for CML therapies despite generics. The acquisition signals growing interest in CML beyond Novartis (NVS), it added. Chronic myeloid leukemia (CML) is a slow-growing blood cancer where the bone marrow produces too many myeloid cells.In this context, Enliven's ELVN-001 is a high-potential investigational therapy with a best-in-class profile, offering a complementary mechanism to the approaches of Novartis’s Asciminib and TERN-701 and multiple strategic paths to value, the firm argued.Clear sees ELVN-001 as a lower-risk, high-upside asset. The late-stage ENABLE-2 trial of ELVN-001 in second line and beyond CML remains on track for the second half of 2026 initiation, pending U.S. Food and Drug Administration’s alignment on dose selection and trial design.<h2 class="st-heading-2">Merck-Terns Deal</h2>Merck said earlier on Wednesday that it has entered into a definitive agreement to acquire Terns for $53.00 per share in cash for an approximate equity value of $6.7 billion in a bid to add TERN-701 to its portfolio. TERN-701 is an experimental therapy currently in development for certain patients with CML. The transaction is expected to close in the second quarter of 2026, the company said, but analysts including RBC Capital and William Blair noted that it expects another bidder to emerge for Terns.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ELVN stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/ELVN">ELVN stock</a> has gained 68% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/salesforce-reportedly-holding-back-on-raises-for-higher-level-employees/cZ3YDSyRISD">Salesforce Reportedly Holding Back On Raises For Higher-Level Employees</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Enliven Therapeutics, Inc. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Terns Buyout Deal Ignites Optimism For Enliven Therapeutics’s Blood Cancer Portfolio

According to Clear Street, the Terns-Merck deal underscores the unmet need and opportunity for safer, more effective chronic myeloid leukemia (CML) therapies.

Equity

According to Clear Street, the Terns-Merck deal underscores the unmet need and opportunity for safer, more effective chronic myeloid leukemia (CML) therapies.


Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up After Analyst Upgrade

Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up Following Analyst Upgrade...

Enliven Therapeutics (NASDAQ:ELVN) Price Target Raised to $45.00

Mizuho upped their price target on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the company an "outperform" rating in a research note on Wednesday...

Enliven Therapeutics (NASDAQ:ELVN) Hits New 12-Month High - Should You Buy?

Enliven Therapeutics (NASDAQ:ELVN) Sets New 52-Week High - Should You Buy...

Enliven Therapeutics (NASDAQ:ELVN) Trading 5.3% Higher - Here's What Happened

Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 5.3% - Still a Buy...

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the five analysts that are covering the firm, MarketBeat reports. One...

Enliven Therapeutics, Inc. $ELVN Shares Bought by HighVista Strategies LLC

HighVista Strategies LLC grew its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 83.1% during the 3rd quarter, according to its most recent 13F filing with the SEC. The...

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.

Enliven Therapeutics Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Current Price	$38.83
Prev Close	$37.79
Open	$37.07
Dividend Yield	0.00%
50-Day Moving Average	$29.46
Beta	1.48
Avg. Volume	1.54M
PE Ratio	-20.90

52-Week High	$40.62
52-Week Low	$13.30
Market Capitalization	$2.32B
EPS (Annual)	-$1.83
Price to Book	5.02
Revenue Per Employee	$0.00

ELVN
Enliven Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ELVN News

ELVNEnliven Therapeutics Inc